Tag Archive for: blood vessel disorder

If approved, the therapy will help the U.S. drugmaker diversify its revenue stream as its blockbuster cancer immunotherapy, Keytruda, moves towards loss of market exclusivity in 2028.

Merck & Co said a therapy it gained through the drugmaker’s $11.5 billion acquisition of Acceleron Pharma last year met the main goal of a late-stage study in patients with a progressive blood vessel disorder.